ORIGINAL PAPER
Body composition assessment by bioelectrical impedance analysis among patients treated with L-dopa for Parkinson’s disease
More details
Hide details
Submission date: 2017-09-07
Final revision date: 2017-10-12
Acceptance date: 2017-11-03
Publication date: 2018-06-30
Medical Studies 2018;34(2):120-126
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Among the consequences of Parkinson’s disease are disorders in body composition and weight loss.
Aim of the research:
An analysis of body composition of patients with Parkinson’s disease treated with L-dopa.
Material and methods:
A group of 32 patients was examined, including 26 (81.25%) females and 6 (18.75%) males. The study was conducted in the Laboratory for Posturology in the Institute of Physiotherapy at the faculty of Medicine and Medical Sciences, Jan Kochanowski University in Kielce. Body composition was assessed using bioelectrical impedance analysis, which consists of the evaluation of resistance to the flow of an electric current.
Results and conclusions:
The majority of body composition parameters remained within the normal ranges. The mean body mass index (BMI) index in patients with Parkinson’ disease was 24.12 kg/m2 and remained within the normal range. The metabolic age of patients was 42.34 years and was considerably lower than the calendar age – 54.28 years. Highly significant differences were observed between males and females according to body height (Z = 3.7541; p = 0.0002), body weight (Z = 3.2592; p = 0.0011), fat mass (%) (Z = 3.1627; p = 0.0016), fat-free mass (kg) (Z = 3.7417; p = 0.0002), muscle mass (kg) (Z = 3.7421; p = 0.0002), visceral fat (Z = 1.9892; p = 0.0467), total body water (kg), total body water content (%) (Z = 3.7428; p = 0.0002), extracellular water (kg) (Z = 3.7448; p = 0.0002), intracellular fluid (kg) (Z = 3.7424; p = 0.0002), and the ratio of extracellular water to total body water (%) (Z = 2.9223; p = 0.0035). There were also significant positive correlations between metabolic age and the Overall Stability Index (r = 0.4057, p = 0.0212) and Front-Back Stability Index (r = 0.3507, p = 0.0490).
REFERENCES (21)
1.
Barichella M, Pinelli G, Iorio L, Cassani E, Valentino A, Pusani C, Ferri V, Bolliri C, Pasqua M, Pezzoli G, Frazzitta G, Cereda E. Sarcopenia and dynapenia in patients with Parkinsonism. J Am Med Dir Assoc 2016; 17: 640-646.
2.
Wilczyński J, Półrola P. Body posture in patients with Parkinson’s disease. Baltic J Health Phys Activity 2017; 9: 87-96.
3.
Cugusi L, Solla P, Serpe R, Carzedda T, Piras L, Oggianu M, Gabba S, Di Blasio A, Bergamin M, Cannas A, Marrosu F, Mercuro G. Effects of a Nordic Walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson’s disease. Neurorehabilitation 2015; 37: 245-254.
4.
Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B 2016; 6: 287-296.
5.
Kubo SI. Membrane lipids as therapeutic targets for Parkinson’s disease: a possible link between Lewy pathology and membrane lipids. Expert Opin Ther Targets 2016; 20: 1301-1310.
6.
Lindskov S, Sjöberg K, Hagell P, Westergren A. Weight stability in Parkinson’s disease. Nutr Neurosci 2016; 19: 11-20.
7.
McCormack A, Chegeni N, Chegini F, Colella A, Power J, Keating D, Chataway T. Purification of alpha-synuclein containing inclusions from human post mortem brain tissue. J Neurosci Methods 2016; 15: 141-150.
8.
McNeely ME, Duncan RP, Earhart GM. A comparison of dance interventions in people with Parkinson disease and older adults. Maturitas 2015; 81: 10-16.
9.
Mielczarek P, Smoluch M, Kotlinska JH, Labuz K, Gotszalk T, Babij M, Suder P, Silberring J. Electrochemical generation of selegiline metabolites coupled to mass spectrometry. J Chromatogr A 2015; 10: 96-103.
10.
Noreik M, Kuhn J, Hardenacke K, Lenartz D, Bauer A, Bührle CP, Häussermann P, Hellmich M, Klosterkötter J,.
11.
Wiltfang J, Maarouf M, Freund HJ, Visser-Vandewalle V, Sturm V, Schulz RJ. Changes in nutritional status after deep brain stimulation of the nucleus basalis of meynert in Alzheimer’s disease-results of a phase I study. J Nutr Health Aging 2015; 19: 812-818.
12.
Strowd RE, Herco M, Passmore-Griffin L, Avery B, Haq I, Tatter SB, Tate J, Siddiqui MS. Association between subthalamic nucleus deep brain stimulation and weight gain: results of a case-control study. Clin Neurol Neurosurg 2016; 140: 38-42.
13.
Vikdahl M, Carlsson M, Linder J, Forsgren L, Håglin L. Weight gain and increased central obesity in the early phase of Parkinson’s disease. Clin Nutr 2014; 33: 1132-1139.
14.
Cassani E, Cereda E, Barichella M, Madio C, Cancello R, Caccialanza R, Zini M, Cilia R, Pezzoli G. Cardiometabolic factors and disease duration in patients with Parkinson’s disease. Nutrition 2013; 29: 1331-1335.
15.
Sheard JM, Ash S, Silburn PA, Kerr GK. Nutritional status in Parkinson’s disease patients undergoing deep brain stimulation surgery: a pilot study. J Nutr Health Aging 2013; 17: 148-151.
16.
Jorgensen HU, Werdelin L, Lokkegaard A, Westerterp KR, Simonsen L. Free-living energy expenditure reduced after deep brain stimulation surgery for Parkinson’s disease. Clin Physiol Funct Imaging 2012; 32: 214-220.
17.
Mann RK, Edwards R, Zhou J, Fenney A, Jog M, Duval C. Comparing movement patterns associated with Huntington’s chorea and Parkinson’s dyskinesia. Exp Brain Res 2012; 218: 639-654.
18.
Cereda E, Cassani E, Barichella M, Spadafranca A, Caccialanza R, Bertoli S, Battezzati A, Pezzoli G. Low cardiometabolic risk in Parkinson’s disease is independent of nutritional status, body composition and fat distribution. Clin Nutr 2012; 31: 699-704.
19.
Markaki E, Ellul J, Kefalopoulou Z, Trachani E, Theodoropoulou A, Kyriazopoulou V, Constantoyannis C. The role of ghrelin, neuropeptide Y and leptin peptides in weight gain after deep brain stimulation for Parkinson’s disease. Stereotact Funct Neurosurg 2012; 90: 104-112.
20.
Cereda E, Cassani E, Barichella M, Caccialanza R, Pezzoli G. Anthropometric indices of fat distribution and cardiometabolic risk in Parkinson’s disease. Nutr Metab Cardiovasc Dis 2013; 23: 264-271.
21.
Bernhardt D, Müller HP, Ludolph AC, Dupuis L, Kassubek J. Body fat distribution in Parkinson’s disease: An MRI-based body fat quantification study. Parkinson Relat Disord 2016; 33: 84-89.